Glimepirid 1 A Pharma

Glimepirid 1 A Pharma is a prescription medication that contains the active ingredient glimepiride, a sulfonylurea class antidiabetic agent. It is supplied as an oral dosage form, with the specific strength not disclosed in the available information. Marketed in the European Union, this product is intended for use under medical supervision to help manage blood glucose levels in adults with type 2 diabetes mellitus as a chronic condition.

Glimepirid 1 A Pharma is indicated for the management of type 2 diabetes mellitus in adults when diet, exercise, and other non‑pharmacologic measures are insufficient.

- Used as monotherapy in patients with mild hyperglycemia. - Combined with metformin or other oral antidiabetics when glycemic control is inadequate. - May be prescribed when insulin therapy is not yet required. - Helps lower fasting and post‑prandial blood glucose levels. - Intended for patients whose pancreatic beta‑cell function is still present. - Can be part of a comprehensive treatment plan that includes lifestyle modification and regular monitoring of HbA1c.

Glimepirid 1 A Pharma may cause a range of adverse effects, most of which are related to its action on insulin secretion. These effects reflect the drug’s influence on glucose metabolism and may vary according to individual patient factors such as age, renal function, and concomitant medications.

Common: - Low blood sugar (hypoglycemia), especially if meals are missed. - Weight gain due to increased insulin activity. - Nausea or mild gastrointestinal discomfort. - Headache or dizziness. - Mild fatigue or feeling of weakness. - Transient visual disturbances such as blurred vision.

Serious: - Severe hypoglycemia leading to loss of consciousness. - Allergic reactions such as rash, itching, or swelling. - Rare cases of liver enzyme elevation.

When prescribing Glimepirid 1 A Pharma, clinicians should consider several precautionary measures to ensure safe and effective use.

- Assess renal and hepatic function before initiating therapy. - Use lower starting doses in elderly patients or those with reduced kidney function. - Monitor blood glucose regularly to detect hypoglycemia early. - Advise patients to maintain consistent meal patterns and avoid skipping meals. - Caution in patients with a history of cardiovascular disease. - Review any history of sulfonylurea allergy before use. - Pregnancy and breastfeeding status should be evaluated, as safety data are limited.

Glimepirid 1 A Pharma can interact with other medicines, affecting blood sugar control or increasing the risk of adverse events.

Avoid: - Concurrent use with other sulfonylureas or meglitinides, which may cause additive hypoglycemia. - Co‑administration with strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that can raise glimepiride plasma levels. - Use with insulin or high‑dose insulin secretagogues without dose adjustment. - Avoid alcohol excess, which can potentiate hypoglycemia.

Use with caution: - Combination with beta‑blockers may mask hypoglycemia symptoms. - Concomitant use of diuretics (especially thiazides) may affect glucose tolerance. - Antidepressants such as SSRIs may require monitoring of glycemic response. - Caution when combined with oral contraceptives, as hormonal changes may alter glucose metabolism.